Alcohol

Co-administration of ethanol with any opioid (heroin, morphine, fentanyl, oxycodone, codeine, methadone, buprenorphine, tramadol, and synthetic analogs) produces synergistic respiratory depression. Forensic toxicology consistently identifies ethanol as the most common co-substance in opioid overdose fatalities.

Co-administration of ethanol with benzodiazepines (alprazolam, diazepam, clonazepam, lorazepam, etc.) produces synergistic sedation and respiratory depression. Polydrug fatalities involving benzodiazepines and ethanol are common.

The combination of ethanol with GHB or GBL is classified as lethal. European poison center data confirm substantially worsened clinical outcomes when GHB/GBL is combined with ethanol. The steep dose-response curve of GHB makes this combination particularly treacherous.

Patients with epilepsy or seizure history face elevated seizure risk during alcohol withdrawal. Even moderate regular consumption followed by cessation can provoke breakthrough seizures. Ethanol also has pharmacokinetic interactions with many anticonvulsant medications.

Any consumption in individuals with a history of AUD carries high relapse risk. Incentive-sensitization of dopamine circuits persists long after acute withdrawal resolves. Even small amounts can trigger escalation to problematic use patterns.

Major depressive disorder, Bipolar disorder, Generalized anxiety disorder, Panic disorder

Chronic alcohol use exacerbates depressive and anxiety symptoms through neurochemical changes. Bidirectional relationship: alcohol worsens depression, depression increases heavy drinking risk. Ethanol also interacts pharmacokinetically and pharmacodynamically with psychotropic medications including SSRIs, mood stabilizers, and antipsychotics.

Patients with cirrhosis or severe alcohol-associated liver disease have critically impaired ethanol metabolism. Any further ethanol exposure accelerates hepatic decompensation and increases mortality risk.

Patients with chronic hepatitis B or C who consume alcohol experience accelerated liver fibrosis progression, increased risk of cirrhosis, and elevated hepatocellular carcinoma risk compared to either risk factor alone.

Heavy chronic drinkers have induced CYP2E1 (2–3× upregulation), which accelerates acetaminophen metabolism to the hepatotoxic metabolite NAPQI. This can produce liver damage at acetaminophen doses considered safe in non-drinkers. Glutathione depletion from chronic alcohol use further reduces NAPQI detoxification capacity.

Patients on disulfiram therapy will experience a severe aversive reaction if ethanol is consumed. While this is the intended therapeutic mechanism, uncontrolled exposure is dangerous and can produce cardiovascular collapse.

Approximately 540 million individuals worldwide (predominantly East Asian descent) carry the ALDH2*2 allele, encoding an essentially inactive ALDH2 enzyme. These individuals experience the 'Asian flushing response' and face dramatically elevated esophageal squamous cell carcinoma risk from alcohol consumption.

Any amount of ethanol during pregnancy poses risk of fetal alcohol spectrum disorders — a continuum of permanent neurodevelopmental and structural defects. No safe threshold has been established. FASD affects an estimated 1 in 20 school-age children in the US.

Ethanol impairs reaction time, motor coordination, visual acuity, and judgment at BAC well below the legal driving limit of 0.08%. Impairment begins at BAC as low as 0.02%. Operating motor vehicles or heavy machinery while under the influence of ethanol poses lethal risk to self and others.